39217-08-8

Usage

Chemical Properties

Light red solid

Uses

2-Chloropyridine-3,4-diamine

InChI:InChI=1/C5H6ClN3/c6-5-4(8)3(7)1-2-9-5/h1-2H,8H2,(H2,7,9)

Upstream product

• 2789-25-5 2-chloro-3-nitropyridin-4-amine 
• 1681-37-4 4-amino-3-nitropyridine 
• 6298-19-7 2-chloro-3-aminopyridine 
• 1312105-92-2 C₁₄H₇ClN₂O₄ 
• 1312105-96-6 C₁₈H₁₆ClN₃O₄ 
• 1312105-99-9 C₁₃H₈ClN₃O₂ 
• 1312105-89-7 3-((tert-butoxycarbonyl)amino)-2-chloroisonicotinic acid 
• 58483-94-6 3-amino-2-chloroisonicotinic acid 
• 209798-48-1 tert-butyl N-(2-chloro-3-pyridinyl)carbamate 
• 14432-12-3 4-Amino-2-chloropyridine 
• 14432-16-7 2-chloro-4-nitropyridine-N-oxide 
• 2402-95-1 2-chloropyridine-N-oxide 
• 109-09-1 2-chloropyridine 

Downstream Products

• 214045-82-6 5-chloropyrido[3,4-b]pyrazine 
• 111326-43-3 10-chloro-dibenzo[f,h]pyrido[3,4-b]quinoxaline 
• 36258-82-9 4-chloro-1H-[1,2,3]triazolo[4,5-c]pyridine 
• 30466-60-5 2-trifluoromethyl-oxazolo[5,4-b]pyridin-7-ylamine 
• 75007-97-5 4-Chloro-2-o-tolyl-1H-imidazo[4,5-c]pyridine 
• 156221-80-6 N-(4-amino-2-chloro-3-pyridyl)cyclopropanecarboxamide 
• 120759-70-8 4-Chloro-1,3-dihydro-imidazo[4,5-c]pyridine-2-thione 
• 153953-01-6 N-(4-amino-2-chloro-3-pyridyl)pentanamide 
• 75008-00-3 2-(4-Bromo-phenyl)-4-chloro-1H-imidazo[4,5-c]pyridine 
• 75007-83-9 4-Chloro-2-(3,5-dinitro-phenyl)-1H-imidazo[4,5-c]pyridine 
• 156221-79-3 N-(4-amino-2-chloro-3-pyridyl)propionamide 
• 75008-01-4 4-Chloro-2-p-tolyl-1H-imidazo[4,5-c]pyridine 
• 149299-08-1 4-chloro-1⁽³⁾H-imidazo[4,5-c]pyridine; hydrochloride 
• 156221-77-1 4-chloro-2-propyl-3H-imidazo<4,5-c>pyridine 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy

Novel substituted purine isosters, were designed and synthesized as potential inhibitors of the Epidermal Growth Factor Receptor (EGFR). The compounds were rationally designed through bioisosteric replacement of the central quinazoline core of lapatinib, an approved drug that inhibits both EGFR and HER2, another important member of this family of receptors. The new target molecules were evaluated as inhibitors of receptor phosphorylation at the cellular level, for their direct inhibitory action on the intracellular receptor kinase domain and for their cytotoxicity against the non-small cell lung cancer cell line A549 and breast cancer HCC1954, cell lines which are associated with overexpression of EGFR and HER2, respectively. The most potent derivatives were further studied for their cellular uptake levels and in vivo pharmacokinetic properties. One compound (23)displayed a noteworthy pharmacokinetic profile, and higher intracellular accumulation in comparison to lapatinib in the A549 cells, possibly due to its higher lipophilicity. This lead compound (23)was assessed for its efficacy in an EGFR positive xenograft model, where it successfully inhibited tumor growth, with a similar efficacy with that of lapatinib and with minimal phenotypic toxicity.

THERAPEUTIC INHIBITORY COMPOUNDS

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

Design and synthesis of purine analogues as highly specific ligands for FcyB, a ubiquitous fungal nucleobase transporter

In the course of our study on fungal purine transporters, a number of new 3-deazapurine analogues have been rationally designed, based on the interaction of purine substrates with the Aspergillus nidulans FcyB carrier, and synthesized following an effective synthetic procedure. Certain derivatives have been found to specifically inhibit FcyB-mediated [3H]-adenine uptake. Molecular simulations have been performed, suggesting that all active compounds interact with FcyB through the formation of hydrogen bonds with Asn163, while the insertion of hydrophobic fragments at position 9 and N6 of 3-deazaadenine enhanced the inhibition.

A convergent synthesis of the imidazopyridine scaffold of fluorescent alkaloid ageladine A

A convergent synthesis of the imidazopyridine scaffold of fluorescent alkaloid ageladine A (1) has been achieved, employing 3-amino-2-chloropyridine as the staring material. A carboxylic acid was introduced using n-butyllithium and dry ice as the key reaction.

CYCLOPENTENOL NUCLEOSIDE COMPOUNDS, INTERMEDIATES FOR THEIR SYNTHESIS AND METHODS OF TREATING VIRAL INFECTIONS

The present invention relates to compounds according to the structure (I), Where B is formula (Ia), formula (Ib) or formula (Ic); A is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A' is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A" is H or OR1, with the proviso that when A' is OR , A is H; and when A is OR2 , A' is H; X is C-R3 or N; Y is C-R3 or N; preferably X or Y is N and X and Y are not both simultaneously N; R3 is H or C1-C3 alkyl; D is H or NHR2; E is absent or H; G is O or NHR2; J is N or C-R4; K is N or C-H; R4 is H, halogen (F, Cl, Br, I), CN, -C(=O)NH2, NH2, NO2, -C=C-H (cis or trans) or -C≡C-H; Ra is H or CH3; Each R1 is independently H, an acyl group, a C1 - C20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group; Each R2 is independently H, an acyl group, a C1 - C20 alkyl or ether group; and Pharmaceutically acceptable salts, solvates or polymorphs thereof.

NOVEL CONDENSED IMIDAZOLE DERIVATIVE

Disclosed is a compound represented by the formula (1) below which has a high DPP-IV inhibitory activity and is improved in safety, toxicity and the like. Also disclosed is a prodrug of such a compound and pharmaceutically acceptable salts of them. (In the formula, R1 represents a hydrogen atom, an optionally substituted alkyl group or the like; R2 and R3 independently represent a hydrogen atom, an optionally substituted alkyl group or the like; R4 and R5 independently represent a hydrogen atom, an optionally substituted alkyl group or the like: R6 represents a hydrogen atom, an optionally substituted aryl group or the like; and -Y-NH2, represents a group represented by the following formula (A): (wherein m is 0, 1 or 2; and R7 may not exist or one or two R7 may exist and independently represent an optionally substituted alkyl group or the like) or the like.]

SYNTHESIS AND BIOLOGICAL EFFECTS OF ACYCLIC ANALOGS OF DEAZAPURINE NUCLEOSIDES

Deaza analogs of three basic types of S-adenosyl-L-homocyteine hydrolase (SAHase) inhibitors, (S)-DHPA (I), eritadenine (II) and AHPA (III), were prepared.Alkylation of 3-deazaadenine (V), 3-deazapurine (VI), 1-deazaadenine (VII) and 4-amino-6-bromo-5-cyanopyrrrolopyrimidine (XXII) with (R)-2,2-dimethyl-4-tosyloxymethyl-1,3-dioxolane (XIIIb), followed by acid hydrolysis, afforded the corresponding (S)-2,3-dihydroxypropyl derivatives XVIIa-XIXa and XXV.Reaction of V and VII with 2,3-O-cyclohexylidene-D-erythronolactone (XXIX) and subsequent removal of the protecting groups in an acid medium gave eritadenine analogs XXVII and XXVIII.Compounds V and VII were alkylated with bromoacetaldehyde diethyl acetal to give N-(2,2-diethoxyethyl) derivatives XXXII and XXXIII from which the substituted acetaldehyde derivatives were liberated in situ and converted into compounds XXX and XXXI by cyanohydrine reaction followed by acid hydrolysis.The alkylations were performed in dimethylformamide with sodium or cesium salts of the bases.Biological activity was observed only with 3-deazaadenine derivatives XVIIa, XXVII and XXX which exhibit both enzyme inhibitory and antiviral activities.